|
3.1 Tabac
|
|
|
|
4.5 Dép., diag. & prono. - Colorectal
|
|
|
Exact Sciences Shares Plunge, Questions Arise for Insurers, Doctors [Xconomy]
|
|
|
|
|
|
The
task force said that computed tomography colonography and Cologuard
might be useful in “select clinical circumstances.” “However, there is
less mature evidence to support these methods, resulting in greater
uncertainty about their net benefits and the most appropriate situations
in which to use them,” the task force wrote.
|
|
|
|
|
|
|
|
Exact Sciences Tumbles on Colon Cancer Screening Snub [TheStreet]
|
|
|
|
|
|
Exact
Sciences CEO Kevin Conroy, speaking on a Tuesday morning conference
call, said the decision by the U.S. Preventive Services Task Force to
omit Cologuard from its draft list of recommended colon cancer screening
tests was "different from what we and most people expected."
|
|
|
|
|
|
|
4.8 Dép., diag. & prono. - Droit
|
|
|
|
5.12 Immunothérapies
|
|
|
The Landscape of Cancer: Immunotherapy Shining Through [The OBR Blog]
|
|
|
|
|
|
Kantar
Health’s newly developed CancerLandscape™ platform identified eight
immunotherapy drugs in Phase 3 clinical trials in the U.S., with 13 in
Phase 2 and 17 in Phase 1; 41 drugs that target PD-1 alone are in
various stages of development, many in preclinical development that may
never make it to clinical trials.
|
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
FDA puts clinical hold on Advaxis cancer drug [Reuters]
|
|
|
|
|
|
Advaxis
said the FDA has asked for additional information to prove that the
drug did not contribute to the patient’s death. Axalimogene filolisbac
is being tested in patients with Human Papilloma Virus-associated
cancers.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
Why the FDA should take more chances on riskier drugs [Pharmalot]
|
|
|
|
|
|
Right
now, the Food and Drug Administration will not approve a drug if there
is more than a 2.5 percent chance that it doesn’t work — no matter which
disease or how poor the prognosis. There is a cold logic to this
approach. And in a recently published paper, Massachusetts Institute of
Technology finance professor Andrew Lo took the FDA to task for not
being more flexible.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.11 Patients
|
|
|
|
6.6 Publications
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|